Patent ID: 9702879
Date: 2017-07-11
CPC Classifications: C07K,C12Q,G01N

Claim:
1. An in vitro method for detecting an invasive carcinoma selected from the group consisting of invasive colon carcinoma, invasive bladder carcinoma, infiltrating ductal breast adenocarcinoma, and invasive pancreas ductal adenocarcinoma, the method comprising: a) detecting in a sample obtained from a patient the proCOL11A1 protein; b) comparing at least one of the following: the detected amount of proCOL11A1 protein in said sample from said patient with the amount of proCOL11A1 protein detected in a control sample; and c) correlating the result obtained in step b) with the presence in the patient of an invasive carcinoma selected from the group consisting of invasive colon carcinoma, invasive bladder carcinoma, infiltrating ductal breast adenocarcinoma, and invasive pancreas ductal adenocarcinoma, wherein the detection step a) is performed with a monoclonal antibody or a fragment of said antibody binding specifically to proCOL11A1 protein, comprising within the heavy chain variable region (V comprising within the light chain variable region (VL) the following complementarity determining regions (CDRs): a CDR comprising the amino acid sequence shown in SEQ ID NO: 6 (SSVNY) [CDR-L1]; a CDR comprising the amino acid sequence YTS [CDR-L2]; and a CDR comprising the amino acid sequence shown in SEQ ID NO: 7 (QQFTSSPWT) [CDR-L3]; and wherein said correlation is an increase in the detected amount of proCOL11A1 protein in said sample from said patient with respect to the amount of proCOL11A1 protein detected in a control sample.